Previous 10 | Next 10 |
Gainers: MGI +117.9% . PHAS +14.0% . NSPR +7.4% . EIGR +4.9% . ARQL +2.7% . More news on: MoneyGram International, Inc., PhaseBio Pharmaceuticals, Inc., InspireMD, Inc., Stocks on the move, , News on ETFs Read more ...
Eiger BioPharmaceuticals (NASDAQ: EIGR ) is up 4.9% in relatively light postmarket trading after noting its avexitide treatment got Breakthrough Therapy designation from the FDA, putting it on a fast track. More news on: Eiger BioPharmaceuticals, Inc., Healthcare stocks news, Stocks on...
PALO ALTO, Calif. , June 17, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced that the Food and Drug Administration (FDA) has granted Breakthrou...
PALO ALTO, Calif. , June 10, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of therapies for rare and ultra-rare diseases, today announced the appointment of Mark Mannebach , PhD, RPh as Vice President of Global R...
PALO ALTO, Calif. , June 5, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of therapies for rare diseases, announced today the appointment of Jeysen Yogaratnam, MB.BCh, BAO, MRCSEd, PhD, MBA as Vice President of Gl...
PALO ALTO, Calif. , May 30, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that David Cory , President and CEO, will present a corporate u...
PALO ALTO, Calif. , May 17, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that David Apelian will step down as the Company's Chief Opera...
Eiger BioPharmaceuticals (NASDAQ: EIGR ): Q1 GAAP EPS of -$0.90 beats by $0.05 . More news on: Eiger BioPharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
PALO ALTO, Calif. , May 9, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today reported financial results for the three months ended March 31, 2019 and ...
PALO ALTO, Calif. , April 30, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that David Cory , President and CEO, will participate and pr...
News, Short Squeeze, Breakout and More Instantly...
Eiger BioPharmaceuticals Inc. Company Name:
EIGR Stock Symbol:
NASDAQ Market:
Eiger BioPharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Nikola Corporation (NKLA) rose 6.5% to $0.95 on volume of 182,734,103 shares WiSA Technologies Inc. (WISA) fell 3.3% to $0.0235 on volume of 160,634,740 shares PROSHARES TRUST (SQQQ) rose 4.7% to $11.12 on volume of 151,373,755 shares...
A look at the top 10 most actives in the United States Sunshine Biopharma Inc. (SBFM) rose 76.0% to $0.1065 on volume of 290,483,542 shares CXApp Inc. (CXAI) rose 151.0% to $6.15 on volume of 236,739,031 shares Nikola Corporation (NKLA) fell 1.0% to $1.03 on volume of 123,276,764 shares ...
Announces “Stalking Horse” Agreement for the Sale of Zokinvy ® (lonafarnib) Patient Access to Zokinvy ® to Continue Uninterrupted PALO ALTO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) today ...